FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
04 janv. 2022 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16 déc. 2021 06h30 HE
|
Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13 déc. 2021 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
22 nov. 2021 12h37 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
09 nov. 2021 06h45 HE
|
Cullinan Oncology, Inc.
Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021 Cullinan MICA and Cullinan Florentine programs to...
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
18 oct. 2021 07h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan” or “the Company”), a biopharmaceutical company focused on developing a diversified pipeline of...
Cullinan Oncology to Participate in Upcoming Investor Conferences
08 sept. 2021 16h01 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences: Morgan...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10 août 2021 06h30 HE
|
Cullinan Oncology, Inc.
Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology pipeline...
Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference
05 août 2021 16h05 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that it will be participating in the 41st Annual Canaccord Genuity Growth...
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
29 juin 2021 08h00 HE
|
Cullinan Oncology, Inc.
CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trialsCullinan will initiate a FIH trial in 3Q21, including a dose escalation cohort followed by dose expansion cohorts as a...